HitGen Inc (688222)

Currency in CNY
22.52
-0.43(-1.87%)
Closed·
688222 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
688222 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
22.3323.00
52 wk Range
8.3526.49
Key Statistics
Bid/Ask
22.52 / 22.53
Prev. Close
22.95
Open
22.91
Day's Range
22.33-23
52 wk Range
8.35-26.49
Volume
16.35M
Average Volume (3m)
19.7M
1-Year Change
124.07%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
688222 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.90
Downside
-24.96%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

HitGen Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

HitGen Inc Company Profile

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; HG153 a Menin-MLL tablet; HG248; and HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation; HGP1069, a ROCK2 inhibitor eye drop. Further, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Additionally, the company focus on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. HitGen Inc. was founded in 2012 and is based in Chengdu, China.

Employees
483
Market
China

Compare 688222 to Peers and Sector

Metrics to compare
688222
Peers
Sector
Relationship
P/E Ratio
138.0x38.7x−0.5x
PEG Ratio
14.260.640.00
Price/Book
6.4x3.5x2.6x
Price / LTM Sales
21.3x6.0x3.3x
Upside (Analyst Target)
−25.0%5.1%43.4%
Fair Value Upside
Unlock10.1%7.1%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 16.90
(-24.96% Downside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.17%
Dividend Yield
0.27%
Industry Median 0.80%
Annualised payout
0.06
Paid annually
5-Years Growth
-13.65%
Growth Streak

Earnings

Latest Release
Apr 25, 2025
EPS / Forecast
0.07 / --
Revenue / Forecast
106.74M / --
EPS Revisions
Last 90 days

688222 Income Statement

FAQ

What Stock Exchange Does HitGen Trade On?

HitGen is listed and trades on the Shanghai Stock Exchange stock exchange.

What Is the Stock Symbol for HitGen?

The stock symbol for HitGen is "688222."

What Is the HitGen Market Cap?

As of today, HitGen market cap is 9.17B.

What Is HitGen's Earnings Per Share (TTM)?

The HitGen EPS (TTM) is 0.17.

When Is the Next HitGen Earnings Date?

HitGen will release its next earnings report on 26 Oct 2025.

From a Technical Analysis Perspective, Is 688222 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has HitGen Stock Split?

HitGen has split 0 times.

How Many Employees Does HitGen Have?

HitGen has 483 employees.

What is the current trading status of HitGen (688222)?

As of 08 Aug 2025, HitGen (688222) is trading at a price of 22.52, with a previous close of 22.95. The stock has fluctuated within a day range of 22.33 to 23.00, while its 52-week range spans from 8.35 to 26.49.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.